

# Nanocarriers for targeted drug delivery

## Benefits and challenges of nanotechnology for medicine

## Russell Maguire

## ENG14131 Advanced Semiconductor Devices


Durham University

November 26, 2018

# Nanocarrier delivery systems

## Introduction

### Nanocarrier structure



### Definition: nanocarrier

- Biocompatible nanoparticle encapsulating a drug


### Characteristics

- Nanometre scale
- Biodegradable
- Non-immunogenic
- Low toxicity
- Hydrophilic
- Soluble

# Targeted drug delivery

## Introduction

How is targeted drug delivery effective?



**Figure 1:** Goal is to increase drug concentration ratio for diseased tissue.

Targets diseased tissue

- Maximise therapeutic effects
- Minimise effective drug dose
- Common targets are solid tumours, inflamed and infected tissue

Avoids healthy tissue

- Minimise toxic side-effects

# Vascular permeability

## Passive targeting

### Definition: vascular permeability

- Tendency for molecules to leak from blood vessels into interstitial space between cells

### Contributing factors

- Permeability enhancers such as *bradykinin* and *nitric oxide*
- Dense and defective blood vessels
- Enhanced vascular permeability has been observed in solid tumours and inflamed tissue [1]

[1] H. Maeda *et al.*, *Journal of controlled release* **65**, 271–284 (2000).

# Enhanced permeability and retention effect

## Passive targeting

Basis for **first generation** nanomedicines [2]

### Definition: EPR effect

- Tendency for nanoparticles to accumulate in **solid tumours** [1]

### Accumulation procedure

- ① Molecules leak into interstitial space due to **enhanced vascular permeability**
- ② **Lymphatic vessels** are compressed by rapidly growing solid tumour [3]
- ③ Large particles become trapped

[1] H. Maeda *et al.*, *Journal of controlled release* **65**, 271–284 (2000).

[2] A. Wicki *et al.*, *Journal of controlled release* **200**, 138–157 (2015).

[3] T. P. Padera *et al.*, *Nature* **427**, 695 (2004).

# Internal stimuli-responsive nanocarriers

## Stimuli-responsive targeting

### Bioindicators used to trigger release

- Tumours have been observed with lower **pH** than healthy tissue [4, 5]
- Individual organelles maintain their own unique pH and **redox potential**
- Intracellular and extracellular space maintain different redox potentials [6]

[4] I. F. Tannock, D. Rotin, *Cancer research* **49**, 4373–4384 (1989).

[5] L. E. Gerweck, K. Seetharaman, *Cancer research* **56**, 1194–1198 (1996).

[6] G. Saito *et al.*, *Advanced drug delivery reviews* **55**, 199–215 (2003).

## External stimuli-responsive nanocarriers

## Stimuli-responsive targeting

## Mechanisms used to externally trigger release

- Electromagnetic fields
- Ultrasound
- Heat
- Light

## Surface ligands

## Active targeting

## Definition: active targeting



Thank you, any questions?

## References

1. H. Maeda *et al.*, *Journal of controlled release* **65**, 271–284 (2000).
2. A. Wicki *et al.*, *Journal of controlled release* **200**, 138–157 (2015).
3. T. P. Padera *et al.*, *Nature* **427**, 695 (2004).
4. I. F. Tannock, D. Rotin, *Cancer research* **49**, 4373–4384 (1989).
5. L. E. Gerweck, K. Seetharaman, *Cancer research* **56**, 1194–1198 (1996).
6. G. Saito *et al.*, *Advanced drug delivery reviews* **55**, 199–215 (2003).